CUE Cue Biopharma
Cue Biopharma earnings company data as of 4:48 AM ET 10/23
History
2 periods, newest first. Each row shows EPS above revenue.
| Period | Date | Metric | Estimate | Actual | Result |
|---|---|---|---|---|---|
| FY2026 Q3 | 11 Nov | EPS | — | — | — |
| Rev | — | — | — | ||
| FY2026 Q2 | 14 Aug | EPS | -1.69 | — | — |
| Rev | — | $7.9M | — |
Insider trades
Open-market buys and sales by CUE's executives, directors and 10% owners in the last 12 months, from their Form 4s
- $100K bought by 1 insider
- None no sales outside a trading plan
- None no planned (10b5-1) sales
-
Pasha Sarraf DirectorBuy$100K 323,857 shares at $0.3100 New stakeTraded Dec 30, 2025 Filed Jan 2
Also filed in the last 12 months, not counted as buying or selling: 15 sales to cover taxes, 10 stock grants, and 3 option exercises.
SEC filings
Recent issuer filings from EDGAR, 16 shown.
| Filed | Form | Detail | Links |
|---|---|---|---|
| SCHEDULE 13G/A | — | Filing Doc | |
| 8-K | 7.01,8.01,9.01 | Filing Doc | |
| SCHEDULE 13D | — | Filing Doc | |
| SCHEDULE 13G | — | Filing Doc | |
| 8-K | 2.02 | Filing Doc | |
| 10-Q | Filing Doc | ||
| 8-K | 5.02 | Filing Doc | |
| 8-K | 1.01,3.02,5.02,8.01,9.01 | Filing Doc | |
| 8-K | 5.02,5.07,9.01 | Filing Doc | |
| 8-K | 5.02,8.01 | Filing Doc | |
| DEF 14A | Filing Doc | ||
| 10-Q | Filing Doc | ||
| 8-K | 9.01 | Filing Doc | |
| 8-K | 1.01,3.02,5.02,8.01,9.01 | Filing Doc | |
| 8-K | 3.03,5.03 | Filing Doc | |
| 8-K | 5.07 | Filing Doc |
No filings match this filter.
Estimates are consensus figures; SEC filings remain the official record. Not investment advice.